Joost Boeckmans

Brussels, BRU 1090, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator.

Human stem cell-derived hepatic cells recapitulate polygenic risk in MASLD development and highlight CD36 as a key mediator.

Journal: Life sciences

Published: January 21, 2026

Administrative coding for alpha-1 antitrypsin deficiency including the pi*ZZ phenotype is accurate in Sweden.

Administrative coding for alpha-1 antitrypsin deficiency including the pi*ZZ phenotype is accurate in Sweden.

Journal: Scandinavian journal of gastroenterology

Published: August 11, 2025

Temporal comorbidity patterns preceding MASLD-related major adverse liver outcomes: a nationwide population-based case-control study in Sweden.

Temporal comorbidity patterns preceding MASLD-related major adverse liver outcomes: a nationwide population-based case-control study in Sweden.

Journal: BMJ public health

Published: June 02, 2025

Impact of PNPLA3 I148M on Drug-Induced Hepatocellular Liver Injury: A Systematic Review and Meta-Analysis.

Impact of PNPLA3 I148M on Drug-Induced Hepatocellular Liver Injury: A Systematic Review and Meta-Analysis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: March 13, 2025

Clinical Utility of Non-Invasive Tests for Liver Fibrosis in People Living With Alpha-1 Antitrypsin Deficiency.

Clinical Utility of Non-Invasive Tests for Liver Fibrosis in People Living With Alpha-1 Antitrypsin Deficiency.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 29, 2024

Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study.

Risk of hepatic decompensation or HCC is similar in patients with ALD- and MASLD-cirrhosis: A population-based cohort study.

Journal: European journal of internal medicine

Published: November 04, 2024

Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.

Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study.

Journal: The Lancet regional health. Europe

Published: September 05, 2024

The importance of patient engagement in the multimodal treatment of MASLD.

The importance of patient engagement in the multimodal treatment of MASLD.

Journal: Communications medicine

Published: June 28, 2024

A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.

A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.

Journal: Toxicology

Published: January 31, 2024

Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study.

Inflammation in liver fibrosis and atrial fibrillation: A prospective population-based proteomic study.

Journal: JHEP reports : innovation in hepatology

Published: January 05, 2024

Liver stiffness as a cornerstone in heart disease risk assessment.

Liver stiffness as a cornerstone in heart disease risk assessment.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: September 25, 2023

Macrophages clear out necrotic liver lesions: a new magic trick revealed.

Macrophages clear out necrotic liver lesions: a new magic trick revealed.

Journal: eGastroenterology

Published: September 01, 2023

Showing 1-12 of 39

Last Updated: 09/26/2026